Bone marrow-derived mesenchymal stem cell transplantation for multiple sclerosis

The aim of this study is to establish the safety of intravenous administration of bone marrow-derived autologous adult human mesenchymal stem cells (MSCs) to patients with multiple sclerosis (MS). Bone marrow-derived mesenchymal stem cells were intravenously administered to patients with secondary progressive MS affecting the visual pathways. After transplantation, improved visual acuity and visual-evoked response latency were recorded, with an increase in optic nerve area, for up to 10 months post-infusion. No significant adverse events were reported.